Jefferies Financial Group Inc. Takes $2.17 Million Position in SAB Biotherapeutics, Inc. $SABS

Jefferies Financial Group Inc. acquired a new position in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 580,328 shares of the company’s stock, valued at approximately $2,170,000.

A number of other large investors also recently added to or reduced their stakes in the stock. Vivo Capital LLC acquired a new position in SAB Biotherapeutics during the third quarter worth $22,954,000. Commodore Capital LP acquired a new position in SAB Biotherapeutics during the third quarter worth $8,847,000. RA Capital Management L.P. acquired a new position in SAB Biotherapeutics during the third quarter worth $8,847,000. Woodline Partners LP acquired a new position in SAB Biotherapeutics during the third quarter worth $5,730,000. Finally, Virtu Financial LLC acquired a new position in SAB Biotherapeutics during the third quarter worth $40,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

SABS has been the subject of a number of research analyst reports. Jefferies Financial Group initiated coverage on shares of SAB Biotherapeutics in a research report on Wednesday, May 20th. They set a “buy” rating and a $11.00 price objective for the company. Chardan Capital upped their price objective on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. HC Wainwright upped their price objective on shares of SAB Biotherapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Wall Street Zen cut shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Finally, Rodman & Renshaw restated a “buy” rating and set a $13.00 price objective on shares of SAB Biotherapeutics in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.00.

SAB Biotherapeutics Price Performance

Shares of NASDAQ SABS opened at $3.81 on Wednesday. The firm has a 50-day simple moving average of $3.81 and a 200-day simple moving average of $3.86. The stock has a market capitalization of $291.31 million, a price-to-earnings ratio of -1.81 and a beta of 0.55. The company has a quick ratio of 11.45, a current ratio of 11.45 and a debt-to-equity ratio of 0.01. SAB Biotherapeutics, Inc. has a 52 week low of $1.60 and a 52 week high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). On average, equities analysts predict that SAB Biotherapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.

SAB Biotherapeutics Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.